

Publizierte Kongressbeiträge

1. **Claus R.**, Berliner D., Bavendiek U., Vodovar N., David S., Patecki M., Launay J.M., Haller H., Hiss M., Balzer M.S. *Soluble neprilysin, NT-proBNP, and growth differentiation factor-15 as biomarkers for heart failure in dialysis patients (SONGBIRD)*, Kidney Week, 2019
2. Balzer M.S., Pankow S., **Claus R.**, Ruben S., Haller H., Einecke G. *Pretransplant dialysis modality and long-term patient and kidney allograft outcome: a 15-year retrospective single-centre cohort study*, Kidney Week, 2019
3. **Ohlendorf F**, Sohns JM, Brunkhorst T, Ross TL, Bengel FM, Derlin T. *Volumetric Ga-68-DOTA-TATE PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Neuroendocrine Tumors*. Nuklearmedizin 2019; 58:166.
4. **Ohlendorf F**, Werner RA, Henkenberens C, Ross TL, Christiansen H, Bengel FM, Derlin T. *Predictive and prognostic impact of blood-based inflammatory biomarkers in patients with gastroenteropancreatic neuroendocrine tumors commencing peptide receptor radionuclide therapy*. Nuklearmedizin 2020; 59:180.
5. Derlin T, Bogdanova N, **Ohlendorf F**, Werner R, Christiansen H, Bengel FM, Henkenberens C. *DNA damage response (DDR) and repair kinetics predict treatment response in patients receiving Lu-177-DOTA-TATE peptide receptor radionuclide therapy for advanced gastro-entero-pancreatic neuroendocrine tumors*. Nuklearmedizin 2020; 59:94.
6. **Schultalbers M.**, Tergast T.L., Kabbani A.-R., Kimmann M., Laser H., Simon N., Manns M.P., Cornberg M., Maasoumy B. *Each additional infection significantly increases mortality in patients with decompensated liver cirrhosis* The International Liver Congress, 2019